Thought Leadership
Axinn Antitrust Insight: FTC Announces New HSR Thresholds for 2022
Axinn Update
January 26, 2022
Axinn Antitrust Insight: U.S. Antitrust Agencies to Significantly Revise and Broaden Merger Guidelines
Axinn Update
January 24, 2022
2021's Biggest Antitrust Developments and What to Expect in 2022
Jeny M. Maier
AHLA Speaking of Health Law
January 18, 2022
Who’s Who Legal – Thought Leaders Competition 2022
Daniel S. Bitton, Lisl J. Dunlop, John D. Harkrider, Michael L. Keeley
January 18, 2022
Top Ten 2022: Provider M&A Faces New Antitrust Headwinds
Lisl J. Dunlop
AHLA Speaking of Health Law
January 14, 2022
Europe: Key Patent Issues Counsel Should Monitor this Year
Paul Zeineddin
Managing IP
January 6, 2022
U.S. Takeaways on OECD Antitrust Policy Discussion
James L. Moore III
Law360
January 5, 2022
Top Ten Issues in Health Law 2022
Lisl J. Dunlop
AHLA Health Law Connections
January 1, 2022
The Center for Biosimilars Interview Series: Legal Perspectives in Biosimilars
Chad A. Landmon
The Center for Biosimilars
December 27, 2021
Environment Has Become a Global Merger Control Issue
Caroline Boisvert
Law360
December 17, 2021
Federal Government Enhances Focus on Labor in Antitrust Reform
Neelesh Moorthy, David R. Pearl
Daily Journal
November 17, 2021
United States: E-Commerce and Big Data Merger Control
Daniel S. Bitton, Melanie Kiser, Leslie C. Overton
GCR: Digital Markets Guide
November 2021
Axinn Antitrust Insight: FTC Increasing Remedy Burdens
Axinn Update
October 28, 2021
Antitrust and Healthcare Inequity
Lisl J. Dunlop
Eleanor M. Fox Liber Amicorum - Antitrust Ambassador to the World
October 27, 2021
Extraterritoriality: Approaches Around the World and Model Analysis
Koren W. Wong-Ervin
Eleanor M. Fox Liber Amicorum - Antitrust Ambassador to the World
October 27, 2021
Remedies in the Context of Multi-Jurisdictional Mergers
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 2021
Best Practices in the Acquisition of a Government Contractor
Rachel J. Adcox, Varnitha Siva
Best Practices in the Acquisition of a Government Contractor
October 7, 2021
Axinn IP Update: Proposed Legislation Aims at "Restoring the America Invents Act"
Rebecca L. Clegg, Christopher M. Gallo, PhD, Joshua S. Reisberg
Axinn Update
October 5, 2021
The Other Side of the Coin: Complementarity in Mergers of Multiproduct Firms
Peter C. Herrick, Craig D. Minerva
Antitrust Magazine Online
October 2021
Axinn Antitrust Insight: Changes Afoot at the FTC
Axinn Update
September 27, 2021
Happy 10th Birthday
Aziz Burgy, Bailey V. Cage**, Aaron Z. Savit, PhD
Intellectual Property Magazine
September 27, 2021
Rethinking the Partnership Model to Foster Inclusion
Rachel J. Adcox
ABA Law Practice Today
September 15, 2021
U.S. Antitrust Enforcement in the Trump Administration
Daniel S. Bitton, Melanie Kiser
Tijdschrift Mededingingsrecht in de Praktijk
August 2021
How I Made Partner: Craig Reiser
Craig M. Reiser
Law.com
August 9, 2021
Second Circuit: Southern District of New York – Edition 2
Lisl J. Dunlop, Evan R. Johnson
Global Competition Review
July 2021
SCOTUS Decides Arthrex: Much Ado About Inter Partes Reviews
Aziz Burgy
Bloomberg Law
July 15, 2021
The Center for Biosimilars Interview: Axinn IP Chair Provides Analysis of Biden Biosimilars Initiative
Chad A. Landmon
The Center for Biosimilars
July 14, 2021
Axinn Antitrust Insight: White House Issues Executive Order Aimed at Increasing Antitrust Enforcement and Promoting Competition
Axinn Update
July 12, 2021
A Tougher M&A Regulatory Environment
Lisl J. Dunlop, Jeny M. Maier
Pharma Manufacturing
June 25, 2021
Health Care Antitrust Enforcement Homes in on Non-Hospital Transactions
Lisl J. Dunlop, Angela M. Farren, Jeny M. Maier
AHLA PG Briefing
June 25, 2021
New U.S. Legislation Creates Momentum for Biosimilars
Ramya Auroprem, Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online
June 25, 2021
Axinn Antitrust Insight: Lina Khan Sworn in as New FTC Chair
Axinn Update
June 17, 2021
FDA's Longtime Approach to New Chemical Entity Designations Now Codified
Ramya Auroprem, Stacie L. Ropka, PhD
Outsourced Pharma and Pharmaceutical Online
June 14, 2021
Labor Markets and the Rise of No-Poach Litigation
Melanie Kiser, Carol Xianxiao Liu
American Bar Association
June 4, 2021
Klobuchar Proposes Bill That Would Overhaul U.S. Antitrust Law
David R. Pearl
Daily Journal
June 1, 2021
Pharmacy Times Interviews
David H. Silverstein
Pharmacy Times
May 26, 2021
Extra-Territoriality: Global Dictionary of Competition Law
Melanie Kiser, Koren W. Wong-Ervin
Global Dictionary of Competition Law, Concurrences
May 21, 2021
Opinion: Purple Book Patent Listings Are Only a First Step
Ted Mathias, Stacie L. Ropka, PhD, Aaron Z. Savit, PhD
The Center for Biosimilars
May 8, 2021
Axinn Antitrust Insight: Supreme Court Limits FTC's Ability to Seek Equitable Monetary Relief
Axinn Update
April 30, 2021
A Lump of Coal: Treatment of Alternative Fuels in FTC v. Peabody Energy
Melanie Kiser
The Pipeline, Spring 2021 Edition
Spring 2021
Jota “Digital Competition” Series Article
Koren W. Wong-Ervin
Jota
April 16, 2021
Health Insurance Compliance Steps After Antitrust Reform
Lisl J. Dunlop, Thomas G. Rohback
Law360
April 7, 2021
Axinn Antitrust Insight: DOJ Continues Criminal Enforcement in Labor Markets
Axinn Update
April 6, 2021
Axinn Antitrust Insight: FTC Challenges Illumina’s Acquisition of Grail
Axinn Update
April 6, 2021
Axinn Antitrust Insight: FTC Launches Multinational Group to Tackle Pharmaceutical Deals
Axinn Update
April 6, 2021
Will Skinny Labelling Survive?
Aziz Burgy, Bailey V. Cage**
Intellectual Property Magazine
March 25, 2021
How Far Can You Go? U.S. Merger Enforcement Under Section 2 of the Sherman Act
Koren W. Wong-Ervin
Our Curious Amalgam
March 22, 2021
International Developments in Healthcare Antitrust Litigation
Angela M. Farren
ABA Antitrust Law Section International Committee
March 2021
If You Can’t Beat Them and You Can’t Join Them: Geisinger and Evangelical’s Settlement with DOJ Limits the Scope of Their Partial Acquisition and Collaboration
Jeny M. Maier
AHLA Health Law Weekly
March 12, 2021
IP and Collaboration
Eric D. Dunbar, Chad A. Landmon
Pharmaceutical Executive
March 11, 2021
Interview on the FDA’s Emergency Use Authorization Process for COVID-19 Vaccines
Chad A. Landmon
Pharmacy Times
March 2021
Axinn IP Update: Where is the Federal Circuit Heading in the Skinny Labeling Case?
Bailey V. Cage**, Chad A. Landmon, David H. Silverstein
Axinn Update
March 4, 2021
A Look at What’s Ahead in the Rapidly Growing Cell Therapy Landscape
David H. Silverstein
Pharmacy Times
February 25, 2021
Axinn IP Update: Federal Circuit Says Functional Patent Claims Must Clear "High Hurdles"
Christopher M. Gallo, PhD, Stacie L. Ropka, PhD, Aaron Z. Savit, PhD
Axinn Update
February 12, 2021
Axinn IP Update: Federal Circuit Agrees to Reconsider Controversial “Skinny Label” Decision
Bailey V. Cage**, Chad A. Landmon, David H. Silverstein
Axinn Update
February 10, 2021
Cost and Opportunity in Suspending Early Merger Clearances
Leslie C. Overton, Sam D. Sherman**
Law360
February 8, 2021
Member Spotlight: Francis H. Morrison
Francis Henry Morrison
Voice of Experience
January 27, 2021
The Next Four Years: Antitrust Enforcement on an Upward Trajectory
Lisl J. Dunlop
Concurrences Competition Law Review
January 19, 2021
How President-Elect Biden’s Cabinet Nominations May Impact Pharmacy This Year
Chad A. Landmon
Pharmacy Times
January 15, 2021
Highlights From the OECD Forum on Competition, Day One
Melanie Kiser
Competition Policy International
January 11, 2021
Highlights From the OECD Roundtable on the Role of Competition Policy in Promoting Economic Recovery
Caroline Boisvert
Competition Policy International
January 11, 2021
Susceptibility of Digital Products to Section 271(g) in the Age of Cloud Computing, Artificial Intelligence, Blockchains, and 3D Printing
David K. Ludwig
The Journal of Robotics, Artificial Intelligence & Law
January 11, 2021
The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
Alex Alfano, Chad A. Landmon
Contract Pharma
January 5, 2021
If You Can’t Beat Them and You Can’t Join Them: Geisinger-Evangelical’s Warning for Partial Acquisitions
Jeny M. Maier
AHLA PG Briefing
January 4, 2021
Frandly Fire
Thomas K. Hedemann, Ted Mathias, Gabriella M. McIntyre, Paul Zeineddin
Intellectual Property Magazine, December 2020 / January 2021 Issue
When Japanese Witnesses Testify in U.S. Courts: Answers to Nine Common Concerns
Donald W. Hawthorne, Francis Henry Morrison, Jason Murata
January 2021
Opinion: The Legal and Regulatory Year in Review
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
December 24, 2020
Our Journey to Voting by Mail-In Ballot in North Carolina in 2020
Francis Henry Morrison
Voice of Experience
December 16, 2020
DOJ's 1st Wage-Fixing Indictment is a Warning to Cos.
James L. Moore III, John W. O'Toole, Tiffany Rider
Law360
December 14, 2020
Balancing Incentives to Innovate in Upstream Wireless Technology Markets with Exit Concerns in Midstream Component Product Markets
Koren W. Wong-Ervin
Douglas H. Ginsburg – An Antitrust Professor on the Bench Liber Amicorum Volume II
December 9, 2020
Antitrust Treatment of Acceleration Provisions in Hatch-Waxman Settlements
Michael L. Keeley
FDLI’s Update Magazine, Winter 2020 Issue
December 7, 2020
How Justice Barrett’s Confirmation Might Impact Patent Eligibility
Joshua S. Reisberg, Aaron Z. Savit, PhD
World IP Review
December 1, 2020
Top 10 IPR Pitfalls at the Institution Stage
Aziz Burgy
ABA Landslide magazine, Vol. 13, No. 2, November / December 2020 Issue
What the Potential Elimination of the Biologics Price Competition and Innovation Act Means for Pharmacy
Chad A. Landmon
Pharmacy Times
December 1, 2020
Axinn FDA Update: Insights on the MODERN Labeling Act
Eric D. Dunbar, Chad A. Landmon
Axinn Update
November 20, 2020
Seeking "Mens Sana in Corpore Sano" in a Pandemic
Francis Henry Morrison
Voice of Experience
November 17, 2020
Buyer Beware: Considerations for a Divestiture Buyer in “Litigating the Fix”
Jeny M. Maier
3 Antitrust Report 22, LexisNexis
November 2020
Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge
Chad A. Landmon
The Center for Biosimilars
November 11, 2020
How to Protect IP Against COVID-19 Scammers Leveraging Social Media Algorithms to Legitimize Fake Products
Joshua S. Reisberg
Thomson Reuters Westlaw
November 10, 2020
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Leslie C. Overton
GCR Insight: E-Commerce Competition Enforcement Guide
November 2020
The 2020 Axinn Survey of U.S. Litigation Involving Japanese Companies
Rachel J. Adcox, Donald W. Hawthorne, Jason Murata, John M. Tanski
November 2020
Another Way to Skin the Cat? Perspectives on Using Section 2 to Challenge the Acquisition of Nascent Competitors
James L. Moore III
The Threshold
October 26, 2020
Managing Timing of Multi-Jurisdictional Review
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 2020
What Lemons Teach Us About Privacy and Competition
John D. Harkrider
ABA Antitrust Magazine
Fall 2020
How to Get Selected and Approved as a Merger Divestiture Buyer
Bryce T. Freeman
ABA Antitrust Counselor
September 2020
Surveying the Landscape
Christopher M. Gallo, PhD, David H. Silverstein
Intellectual Property Magazine
September 29, 2020
Can the COVID Experience with Remote Litigation Lead to More Cost-Effective U.S. Litigation for Japanese Companies?
Donald W. Hawthorne
Axinn Updates
September 2020
Practical Advice for Japanese Businesses When Coronavirus Prevents Performance of Contracts Governed by U.S. Law
Donald W. Hawthorne
Axinn Updates
September 2020
Axinn FDA Update: A Difficult Analysis Is Not Necessarily a Deferential Analysis
Alex Alfano, Chad A. Landmon
Axinn Update
September 21, 2020
Tuning in to Covered Business Method Review's Series Finale
Eric Krause, Pan Lee
Law360
September 15, 2020
Acquisitions of Potential Competitors: The U.S. Approach and Calls for Reform
James L. Moore III, Koren W. Wong-Ervin
August 19, 2020
Liability for Japanese Companies Under U.S. Securities Laws: The Risks in Unsponsored ADRs
Donald W. Hawthorne
Axinn Updates
August 2020
Making It Rain: Rachel Adcox
Rachel J. Adcox
ABA Law Practice Today
August 14, 2020
FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors
Chad A. Landmon
Cell & Gene
August 6, 2020
FDA Informal Guidance Process
Alex Alfano, Chad A. Landmon
Lexis Practice Advisor
July 30, 2020
Second Circuit: Southern District of New York
Lisl J. Dunlop
GCR Insight: U.S. Courts Annual Review
July 24, 2020
Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
July 21, 2020
Highlights From OECD Roundtable on Conglomerate Mergers
David R. Pearl
Law360
July 13, 2020
Inclusion Matters, Now More Than Ever: Practical Suggestions for Making a Difference
Jason Murata
AIPLA Innovate Magazine
July 10, 2020
Axinn IP Update: District Court Retains Subject Matter Jurisdiction But Grants Dismissal After Paragraph III Conversion
Ricardo Camposanto, Chad A. Landmon, Ted Mathias
Axinn Update
July 8, 2020
Break Up Denny’s
John D. Harkrider
Competition Policy International
July 8, 2020
Assessing the New DOJ, FTC Vertical Merger Guidelines
John D. Harkrider, Koren W. Wong-Ervin
Law360
July 6, 2020
IPR: The End of the Road for Fifth Amendment Challenges?
Aziz Burgy
World IP Review
July 6, 2020
Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online / Biosimilar Development
June 23, 2020
GCR Interview: Nascent Acquisitions
Koren W. Wong-Ervin
Global Competition Review
June 12, 2020
Open Source Patent Licenses: Pitfalls and Opportunity
Chad A. Landmon
Bloomberg Law
June 5, 2020
A Lawyer's Guide to Client Service Continuity Planning
Craig M. Reiser, Thomas G. Rohback, Eva Yung
Law360
May 22, 2020
AmEx: Beyond Transaction Platforms and Section 1
Koren W. Wong-Ervin
Competition Policy International
May 14, 2020
6 Lessons on Jury Advocacy in the Wake of a Crisis
Francis Henry Morrison, John M. Tanski
Law360
May 11, 2020
ABA SciTech Brief Short Video on COVID-19: FDA Emergency Use Authorizations
Chad A. Landmon
American Bar Association
May 8, 2020
Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
May 4, 2020
Challenging Consummated Mergers Under Section 2
Koren W. Wong-Ervin
Competition Policy International
May 3, 2020
Do You Have to Put Up With That? Legal Protections in the Context of Antitrust Law Investigations in the U.S. and E.U.
Nicholas E.O. Gaglio, Lindsey Strang
Compliance Berater
April 28, 2020
Attorney-Client Privilege in the United States: Recent Trends in its Application to Japanese Patent Professionals
Jason Murata, John M. Tanski
AIPPI Journal
April 2020
A Close Look at European Union's AI Regulation Proposal
Thomas K. Hedemann, Matthew S. Murphy, Brooke J. Oppenheimer
Law360
April 22, 2020
Insulin Under the BPCIA: Opportunities and Obstacles
Ted Mathias, Stacie L. Ropka, PhD
Biosimilar Development
April 22, 2020
FDA’s Emergency Use Authorizations: Aggressive Action Taken to Combat COVID-19
Chad A. Landmon
Contract Pharma
April 20, 2020
How to Combat IP-Facilitated Digital Fraud During Pandemic
Joshua S. Reisberg
Law360
April 20, 2020
Assessing Monopoly Power or Dominance in Platform Markets
Koren W. Wong-Ervin
American Bar Association
April 15, 2020
The Risks of Radicalism: Exacerbating Harms from Type I Errors
James L. Moore III, Koren W. Wong-Ervin
Competition Policy International
April 9, 2020
Virus Heightens Importance of Drug Shortage Reports to FDA
Chad A. Landmon
Law360
April 2, 2020
FDA Emergency Use Authorizations
Chad A. Landmon
Lexis Practice Advisor Journal
April 1, 2020
Axinn IP Update: Prosecution Counsel Beware: Statutory Bars and Inequitable Conduct
Eric D. Dunbar
Axinn Update
March 19, 2020
The 2019 Axinn Survey of U.S. Litigation Involving Japanese Companies
Rachel J. Adcox, Donald W. Hawthorne, Jason Murata, John M. Tanski
March 2020
Balancing Settlements, Motions After Fed. Circ. Serta IP Ruling
Alex Alfano, Stacie L. Ropka, PhD
Law360
March 16, 2020
Navigating Uncertainty in Digital Health Patent Eligibility
Ross E. Blau, Joshua S. Reisberg
Law360
March 2, 2020
Axinn IP Update: Six Patents Directed to Humanized Monoclonal Antibodies Fall at PTAB
Ross E. Blau, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
February 27, 2020
What ACA's Uncertain Future Means for Biologics Patents
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
Law360
February 27, 2020
Chevron’s Hard-Hitting Footnote Nine Revived by Kisor v. Wilkie and Recent Decisions on Deference
Alex Alfano, Chad A. Landmon
FDLI
February 21, 2020
Axinn IP Update: Settlement Practice in Light of Pending Motions
Alex Alfano, Stacie L. Ropka, PhD
Axinn Update
February 20, 2020
A Deep Dive Into the Antitrust Claims Against Facebook
Daniel S. Bitton
The Daily Journal
February 14, 2020
Quest Integrity v. Cokebusters Puts Cloud-Based Medical Diagnostic Patents at Risk of On-Sale Bar
David K. Ludwig, Matthew S. Murphy
Medical Device and Diagnostic Industry
February 7, 2020
FDA Administrative Decision Challenges
Alex Alfano, Chad A. Landmon
Lexis Practice Advisor
January 30, 2020
Pharmaceutical Experience Matters in Defending Pharmaceutical Securities Cases
Matthew J. Becker, Donald W. Hawthorne, Chad A. Landmon
Axinn Update
January 2020
Axinn IP Update: SCOTUS Passes on Refining Subject Matter Eligibility Doctrine
Thomas K. Hedemann, Gabriella M. McIntyre
Axinn Update
January 13, 2020
Method of Treatment Eligibility
Aziz Burgy, Christopher M. Gallo, PhD, Gabriella M. McIntyre
Intellectual Property Magazine
January 9, 2020
Axinn IP Update: No “Single-Entity” Requirement for Section 271(g) Liability
Ricardo Camposanto, Thomas K. Hedemann, David K. Ludwig
Axinn Update
December 30, 2019
Axinn IP Update: Federal Circuit Addresses BPCIA Safe Harbor, Damages
Ted Mathias, Matthew S. Murphy
Axinn Update
December 19, 2019
Open the Floodgates: The Potential Impact on Litigation Against FDA if the Supreme Court Reverses or Curtails Chevron Deference
Alex Alfano, Chad A. Landmon
FDLI
December 18, 2019
Who’s Who Legal – Thought Leaders Competition
Daniel S. Bitton, Lisl J. Dunlop, John D. Harkrider
Who’s Who Legal
December 2019
3 Strategies to Manage Case Scope in ANDA Patent Litigation
Aziz Burgy, Eric D. Dunbar, Christopher M. Gallo, PhD, Brett Garrison
Law360
December 10, 2019
Little Impact Post-Arthrex for Biologic Patents at the PTAB
Gabriella M. McIntyre, Stacie L. Ropka, PhD
The Center for Biosimilars
December 3, 2019
U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?
Chad A. Landmon
IPWatchdog
November 25, 2019
Fed Circ. Ruling May Affect Eligibility of Life Sciences Patents
David K. Ludwig, Ted Mathias
Law360
November 21, 2019
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Leslie C. Overton
GCR Insight: E-Commerce Competition Enforcement Guide
November 20, 2019
Can the FDA Salvage Interchangeable Follow-On Biologics?
Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online / Biosimilar Development
November 19, 2019
Axinn IP Update: Section 287(c) Immunity Has Its Limits
Ross E. Blau, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
November 18, 2019
Curing the Drug Label as Prior Art Malady at the PTAB
Aziz Burgy, Christopher M. Gallo, PhD
IPWatchdog
November 13, 2019
New Calif. Pay-For-Delay Law May Hurt Those It Aims to Help
Chantelle D. Ankerman, Chad A. Landmon
Law360
November 5, 2019
Protecting Intellectual Property in the Era of Intelligent Machines
Thomas K. Hedemann, Matthew S. Murphy
Connecticut Bar Association
Fall 2019
Let Me Ride: No Short-Cuts in the Antitrust Analysis of Ride Hailing
Daniel S. Bitton, David R. Pearl
CLA: Competition, Fall 2019, Vol 29, No. 2
Fall 2019
Axinn IP Update: No Collateral Estoppel after PTAB Ruling on IPR
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
October 9, 2019
Failure to Launch: The Patent Thicket Delay of US Biosimilars
Chantelle D. Ankerman, Ted Mathias, Stacie L. Ropka, PhD
Law360
October 9, 2019
Axinn IP Update: PTAB Abused its Discretion in Denying Patentee Leave to Correct Chain of Priority
Alex Alfano, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
October 4, 2019
Managing Timing of Multi-Jurisdictional Review
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 1, 2019
Fed. Circ. Muddies Waters on Method-Of-Treatment Patents
Thomas K. Hedemann, David K. Ludwig
Law360
September 4, 2019
Fixing the Follow-On Insulin Regulatory Approval "Dead Zone"
Christopher M. Gallo, PhD, Chad A. Landmon
BioSimilar Development
September 4, 2019
Axinn IP Update: Federal Circuit Says Method of Treatment Claims Are Not Per Se Eligible Under Section 101
Ross E. Blau, Ted Mathias
Axinn Update
August 29, 2019
Can We Have Mergers Without Tears? Understanding the Basics of Merger Review
Michael L. Keeley
Our Curious Amalgam
August 26, 2019
Recent FDA Court Decision Shows Potential Impact of SCOTUS Deference Decision
Alex Alfano, Ashton Copeland, Chad A. Landmon
Bloomberg Law and Bloomberg Big Law Business
August 20, 2019
Axinn Insights on U.S. Litigation for Japanese Companies: The Duty to Preserve Documents and Implement Litigation Holds in U.S. Civil Litigation
Rachel J. Adcox, Donald W. Hawthorne, Jason Murata, John M. Tanski
August 19, 2019
How 2 Recent Court Cases Could Impact Follow-On Biologics Strategy
Stacie L. Ropka, PhD, Aaron Z. Savit, PhD
Biosimilar Development
July 23, 2019
What High Court's Kisor Ruling Means for FDA Decisions
Alex Alfano, Ashton Copeland, Chad A. Landmon
Law360
July 16, 2019
UnitedHealth-DaVita and Trends in Vertical Merger Enforcement
Jeny M. Maier
AHLA PG Briefing
July 11, 2019
FDA's Aggressive Enforcement Against Stem Cell Companies Starting to Ripen
Chad A. Landmon
Bloomberg BNA Insights
June 27, 2019
How I Made Partner: Jeny Maier
Jeny M. Maier
Law.com
June 19, 2019
Judge Moves Aetna / CVS Deal Into Unchartered Tunney Act Waters
Lisl J. Dunlop, Jeny M. Maier
Bloomberg Law
June 4, 2019
Biologic Labels and Induced Patent Infringement: A Perspective on Evolving U.S. Law
Stacie L. Ropka, PhD
BioProcess International
May 17, 2019
Information Exchange Counseling in the Digital Age
Kail J. Jethmalani
The Antitrust Counselor
May 15, 2019
Axinn IP Update: FDA Issues Final Guidance on Interchangeability of Biologics
Christopher M. Gallo, PhD, Stacie L. Ropka, PhD
Axinn Update
May 14, 2019
Who’s Who Legal – Thought Leaders Competition and Thought Leaders Global Elite
John D. Harkrider
Who’s Who Legal
May 9, 2019
Navigating Vertical Mergers in Healthcare Through a Shifting Enforcement Landscape
Lisl J. Dunlop
Competition Policy International
May 7, 2019

View Archived Thought Leadership ›

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.